June 4, 2021 07:21 AM EDT

Bristol Myers sued over $6B Celgene CVR as trustee claims 'blatant misconduct' for liso-cel delays

Max Gelman

Senior Editor

After Bristol Myers Squibb’s $74 billion buyout of Celgene, the industry intensely scrutinized whether or not the Big Pharma would ultimately hit its drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers sued over $6B Celgene CVR as trustee claims 'blatant misconduct' for liso-cel delays

Max Gelman

Senior Editor

Sign up to read this article for free.

Safety concerns and trial holds for pediatric RSV vaccines prompt caution from FDA adcomm

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

'Serious liver injury' cases lead FDA to call for monitoring of Ocaliva patients

Pfizer shares positive Phase 3 results in breast cancer subset

Lonza looks to depart capsule and health ingredients as it undergoes restructure

The key to faster, more impactful research? Put patients in the driver’s seat

Bris­tol My­ers sued over $6B Cel­gene CVR as trustee claims 'bla­tant mis­con­duc­t' for liso-cel de­lays

Max Gelman

Senior Editor

Sign up to read this article for free.

Safe­ty con­cerns and tri­al holds for pe­di­atric RSV vac­cines prompt cau­tion from FDA ad­comm

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

'Se­ri­ous liv­er in­jury' cas­es lead FDA to call for mon­i­tor­ing of Ocali­va pa­tients

Pfiz­er shares pos­i­tive Phase 3 re­sults in breast can­cer sub­set

Lon­za looks to de­part cap­sule and health in­gre­di­ents as it un­der­goes re­struc­ture

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Bristol Myers sued over $6B Celgene CVR as trustee claims 'blatant misconduct' for liso-cel delays

Safety concerns and trial holds for pediatric RSV vaccines prompt caution from FDA adcomm

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

'Serious liver injury' cases lead FDA to call for monitoring of Ocaliva patients

Pfizer shares positive Phase 3 results in breast cancer subset

Lonza looks to depart capsule and health ingredients as it undergoes restructure

The key to faster, more impactful research? Put patients in the driver’s seat